Iatrogenic Anemia

 Iatrogenic Anemia: Recognition, Prevention, and Management in Modern Clinical Practice

Dr Neeraj Manikath, claud.Ai

Abstract

Background: Iatrogenic anemia represents a significant yet underrecognized complication of medical care, affecting up to 95% of critically ill patients and contributing substantially to morbidity in hospitalized patients. This condition results from diagnostic phlebotomy, medication-induced hemolysis or bone marrow suppression, and procedural blood loss.

Objective: To provide a comprehensive review of iatrogenic anemia pathophysiology, risk factors, clinical impact, and evidence-based prevention and management strategies.

Methods: Systematic review of current literature on iatrogenic anemia, including epidemiological studies, pathophysiological mechanisms, and therapeutic interventions.

Results: Iatrogenic anemia occurs through multiple mechanisms including excessive phlebotomy (contributing 40-70% of cases), drug-induced bone marrow suppression, hemolysis, and procedural blood loss. High-risk populations include critically ill patients, elderly individuals, and those with chronic diseases. Prevention strategies include phlebotomy reduction protocols, point-of-care testing, and medication monitoring.

Conclusions: Iatrogenic anemia is a preventable condition requiring systematic approaches to minimize unnecessary blood draws, optimize diagnostic testing, and implement evidence-based transfusion thresholds.

Keywords: iatrogenic anemia, hospital-acquired anemia, phlebotomy, medication-induced anemia, transfusion

Introduction

Iatrogenic anemia, defined as anemia directly caused by medical interventions, represents one of the most common preventable complications in hospitalized patients. The term encompasses anemia resulting from diagnostic blood sampling, medication administration, and medical procedures. Despite its high prevalence and significant clinical impact, iatrogenic anemia remains inadequately recognized and addressed in clinical practice.

The economic burden of iatrogenic anemia is substantial, with increased length of stay, higher transfusion requirements, and elevated healthcare costs. More importantly, the clinical consequences include increased mortality, delayed wound healing, cognitive impairment, and reduced quality of life, particularly in vulnerable populations such as critically ill and elderly patients.

This review examines the multifaceted nature of iatrogenic anemia, providing clinicians with evidence-based strategies for recognition, prevention, and management in contemporary medical practice.

 Epidemiology and Clinical Burden

 Prevalence and Incidence

Iatrogenic anemia affects a significant proportion of hospitalized patients, with incidence rates varying by clinical setting. In intensive care units, studies demonstrate that 95% of patients develop anemia during their stay, with iatrogenic causes contributing to 40-70% of cases. Medical and surgical wards report lower but still substantial rates, ranging from 30-60% of patients developing hospital-acquired anemia.

The cumulative effect of diagnostic blood loss is particularly striking in critically ill patients, where daily phlebotomy volumes can reach 40-70 mL, equivalent to one unit of blood over 7-10 days. Pediatric populations are disproportionately affected due to their smaller blood volumes, with premature infants being especially vulnerable.

 Economic Impact

The financial implications of iatrogenic anemia are multifaceted. Direct costs include increased transfusion requirements, with each unit of red blood cells costing approximately $200-300, not including administration and monitoring costs. Indirect costs encompass prolonged hospital stays, with anemic patients experiencing 1-2 additional days of hospitalization on average.

The downstream effects of anemia-related complications, including increased infection rates, delayed surgical procedures, and rehabilitation requirements, further amplify healthcare expenditures. Conservative estimates suggest that preventing iatrogenic anemia could reduce healthcare costs by 15-20% in high-risk populations.

 Pathophysiology and Mechanisms

 Phlebotomy-Related Blood Loss

Diagnostic phlebotomy represents the most significant contributor to iatrogenic anemia in hospitalized patients. The average blood draw ranges from 10-20 mL per sampling event, but critically ill patients may undergo 15-20 blood draws daily, resulting in cumulative losses of 150-400 mL per day.

The physiological response to acute blood loss includes increased erythropoietin production and enhanced iron mobilization. However, in hospitalized patients, these compensatory mechanisms are often blunted by inflammatory conditions, nutritional deficiencies, and concurrent medications. The normal erythropoietic response requires 5-7 days to increase red blood cell production significantly, making patients vulnerable to progressive anemia from repeated blood sampling.

Drug-Induced Mechanisms

Medication-induced anemia occurs through several distinct pathophysiological pathways:

Bone Marrow Suppression: Chemotherapeutic agents, antibiotics (particularly chloramphenicol and sulfonamides), and immunosuppressive medications directly inhibit erythropoiesis. The mechanism typically involves interference with DNA synthesis, cell cycle progression, or stem cell proliferation.

Hemolytic Anemia: Drug-induced hemolysis can occur through immune-mediated mechanisms (drug-dependent antibodies) or direct oxidative damage to red blood cells. Medications commonly associated with hemolysis include antimalarials, sulfonamides, and certain antibiotics in patients with glucose-6-phosphate dehydrogenase deficiency.

Iron Deficiency:Proton pump inhibitors and H2 receptor antagonists can induce iron deficiency anemia by reducing gastric acid production, thereby impairing iron absorption. Long-term use of these medications, particularly in elderly patients, can lead to progressive iron depletion.

Renal Effects: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers can reduce erythropoietin production, particularly in patients with underlying chronic kidney disease.

 Procedural Blood Loss

Surgical and interventional procedures contribute significantly to iatrogenic anemia through direct blood loss and post-procedural bleeding. Major surgical procedures can result in blood losses ranging from 200-2000 mL, depending on the complexity and duration of the operation.

Minimally invasive procedures, while associated with reduced blood loss compared to open surgery, still contribute to cumulative anemia when performed repeatedly. Endoscopic procedures, cardiac catheterizations, and percutaneous interventions each carry specific bleeding risks that must be considered in the overall assessment of iatrogenic anemia.

 Risk Factors and Vulnerable Populations

Patient-Related Risk Factors

Several patient characteristics predispose individuals to developing iatrogenic anemia:

Age:Elderly patients are at increased risk due to reduced bone marrow reserve, multiple comorbidities, and polypharmacy. The normal aging process results in decreased erythropoietic capacity and reduced iron stores, making older adults more susceptible to anemia from minimal blood losses.

Chronic Diseases: Patients with chronic kidney disease, heart failure, cancer, and inflammatory conditions have baseline alterations in erythropoiesis that amplify the impact of iatrogenic blood loss. Chronic kidney disease patients have reduced erythropoietin production, while inflammatory conditions suppress bone marrow response through cytokine-mediated mechanisms.

Nutritional Status: Iron, vitamin B12, and folate deficiencies compromise the hematopoietic response to blood loss. Hospitalized patients frequently have suboptimal nutritional status, further impairing their ability to compensate for iatrogenic blood loss.

Baseline Hemoglobin: Patients with pre-existing anemia have limited physiological reserve and are more likely to develop clinically significant anemia from additional blood loss.

Healthcare-Related Risk Factors

System-level factors contributing to iatrogenic anemia include:

Intensive Care Setting: The complex monitoring requirements and frequent laboratory testing in ICUs create an environment of excessive phlebotomy. Studies demonstrate that ICU patients undergo an average of 3-5 blood draws per day, with some patients experiencing more than 10 daily sampling events.

Teaching Hospital Status: Academic medical centers often have higher rates of iatrogenic anemia due to increased laboratory testing for educational purposes and research protocols. The presence of multiple care teams can lead to duplicative testing and inadequate communication regarding laboratory results.

Length of Stay: Prolonged hospitalization increases cumulative blood loss and medication exposure, creating a time-dependent risk for developing iatrogenic anemia.

 Clinical Manifestations and Diagnosis

 

Symptomatology

The clinical presentation of iatrogenic anemia parallels that of anemia from other causes but may be complicated by the underlying medical condition requiring hospitalization. Common symptoms include fatigue, weakness, dyspnea on exertion, and reduced exercise tolerance. In elderly patients, cognitive impairment and increased fall risk may be prominent features.

Cardiovascular manifestations include tachycardia, palpitations, and in severe cases, high-output heart failure. Patients with underlying coronary artery disease may experience angina or myocardial infarction when hemoglobin levels fall below critical thresholds.

Laboratory Evaluation

The diagnosis of iatrogenic anemia requires careful analysis of hemoglobin trends in relation to medical interventions. Key laboratory parameters include:

Complete Blood Count:Serial hemoglobin and hematocrit measurements should be trended to identify the rate and pattern of decline. A decrease of more than 1 g/dL per day in the absence of obvious bleeding sources suggests significant iatrogenic blood loss.

Reticulocyte Count: An appropriate reticulocytic response (reticulocyte count >2%) indicates intact bone marrow function, while a blunted response suggests bone marrow suppression or nutritional deficiency.

Iron Studies:Serum iron, total iron-binding capacity, and ferritin levels help differentiate iron deficiency from anemia of chronic disease. In hospitalized patients, ferritin may be elevated due to inflammation, making transferrin saturation a more reliable indicator of iron deficiency.

Peripheral Blood Smear: Morphological examination can reveal evidence of hemolysis (spherocytes, schistocytes), nutritional deficiencies (hypersegmented neutrophils, oval macrocytes), or drug-induced changes.

 Differential Diagnosis

Distinguishing iatrogenic anemia from other causes requires systematic evaluation of potential contributing factors:

Occult Bleeding:Gastrointestinal bleeding, particularly in patients receiving anticoagulation or antiplatelet therapy, must be excluded through appropriate testing.

Hemolysis: Laboratory evidence of hemolysis includes elevated lactate dehydrogenase, decreased haptoglobin, and increased indirect bilirubin.

Chronic Disease: Anemia of chronic disease is characterized by low serum iron with normal or elevated ferritin and reduced total iron-binding capacity.

Nutritional Deficiencies: B12 and folate deficiencies can be identified through direct measurement of vitamin levels and assessment of homocysteine and methylmalonic acid.

 Prevention Strategies

 Phlebotomy Reduction Programs

Systematic approaches to reducing diagnostic blood loss have demonstrated significant success in preventing iatrogenic anemia:

Blood Conservation Protocols: Standardized protocols limiting the frequency and volume of blood draws can reduce total phlebotomy by 30-50%. These protocols typically specify minimum intervals between tests, eliminate routine "standing orders," and require justification for frequent monitoring.

Pediatric-Sized Tubes:Using smaller collection tubes (2-3 mL vs. standard 5-7 mL tubes) can reduce blood loss by 40-60% while maintaining diagnostic accuracy for most laboratory tests.

Point-of-Care Testing: Bedside glucose monitoring, arterial blood gas analysis, and hemoglobin measurement require minimal blood volumes (0.1-0.5 mL) compared to traditional laboratory testing.

Closed-Loop Sampling Systems:These systems allow blood sampling from arterial or central venous catheters without blood loss, returning unused blood to the patient after testing.

 Medication Management

Preventing drug-induced anemia requires proactive medication review and monitoring:

Risk Assessment:Systematic screening for medications with hematological toxicity should be incorporated into medication reconciliation processes. High-risk medications require enhanced monitoring with regular complete blood counts.

Dose Optimization: Using the minimum effective dose and shortest duration of therapy for potentially myelosuppressive medications reduces the risk of bone marrow suppression.

Alternative Therapies:When possible, substituting medications with lower hematological toxicity can prevent drug-induced anemia. For example, H2 receptor antagonists may be preferred over proton pump inhibitors in patients at risk for iron deficiency.

Prophylactic Supplementation: Iron, B12, and folate supplementation may be appropriate for patients receiving medications that interfere with absorption or utilization of these nutrients.

Procedural Modifications

Surgical and procedural techniques can be modified to minimize blood loss:

Minimally Invasive Approaches: Laparoscopic and endoscopic techniques typically result in reduced blood loss compared to open procedures.

Hemostatic Agents:Topical hemostatic agents, fibrin sealants, and antifibrinolytic medications can reduce procedural bleeding.

Blood Conservation Techniques: Intraoperative blood salvage, hemodilution, and controlled hypotension can minimize blood loss during major surgical procedures.

 Management Approaches

Transfusion Strategies

Contemporary transfusion medicine emphasizes restrictive transfusion thresholds based on robust clinical evidence:

Hemoglobin Thresholds: For most hospitalized patients, transfusion is recommended when hemoglobin falls below 7 g/dL. Higher thresholds (8-9 g/dL) may be appropriate for patients with cardiovascular disease, ongoing bleeding, or severe symptoms.

Single-Unit Transfusion: Transfusing one unit of red blood cells at a time, followed by reassessment, reduces the risk of overtransfusion and associated complications.

Alternatives to Transfusion: Iron supplementation, erythropoiesis-stimulating agents, and nutritional support may be effective alternatives or adjuncts to transfusion in appropriate patients.

 Pharmacological Interventions

Several medications can support the management of iatrogenic anemia:

Iron Supplementation: Intravenous iron is preferred in hospitalized patients due to superior bioavailability and rapid correction of iron deficiency. Various formulations (iron sucrose, ferric carboxymaltose, iron dextran) have different safety profiles and administration requirements.

Erythropoiesis-Stimulating Agents (ESAs): ESAs can stimulate red blood cell production in patients with chronic kidney disease or cancer-related anemia. However, their use requires careful monitoring due to potential cardiovascular and thrombotic risks.

Vitamin Supplementation:B12 and folate supplementation should be provided to patients with documented deficiencies or those at high risk for deficiency.

Supportive Care

Non-pharmacological interventions play an important role in managing iatrogenic anemia:

Activity Modification: Adjusting physical activity levels and providing assistive devices can help patients cope with anemia-related fatigue and weakness.

Oxygen Therapy: Supplemental oxygen may be beneficial for patients with severe anemia and compromised oxygen delivery, particularly those with underlying cardiopulmonary disease.

Nutritional Support:Ensuring adequate protein, iron, and vitamin intake supports erythropoiesis and recovery from anemia.

 Quality Improvement and System-Level Interventions

 Blood Management Programs

Comprehensive blood management programs integrate multiple strategies to prevent and manage iatrogenic anemia:

Multidisciplinary Teams: Involving physicians, nurses, pharmacists, and laboratory personnel in blood conservation efforts ensures coordinated care and sustained improvement.

Clinical Decision Support:Electronic health record alerts and order sets can guide appropriate laboratory testing and transfusion decisions.

Performance Monitoring:Regular tracking of phlebotomy volumes, transfusion rates, and anemia incidence provides feedback on program effectiveness.

 Education and Training

Healthcare provider education is essential for successful anemia prevention programs:

Clinical Guidelines:Clear, evidence-based guidelines for laboratory testing, transfusion, and anemia management should be readily accessible to all providers.

Case-Based Learning: Educational programs using real clinical scenarios help providers understand the impact of their decisions on patient outcomes.

Competency Assessment: Regular assessment of provider knowledge and skills ensures consistent application of best practices.

Technology Solutions

Innovative technologies can support blood conservation efforts:

Non-Invasive Monitoring:Continuous hemoglobin monitoring devices can reduce the need for blood sampling while providing real-time information about patient status.

Laboratory Information Systems: Advanced laboratory systems can optimize test ordering, reduce duplicate testing, and provide decision support for providers.

Critically Ill Patients

ICU patients represent the highest-risk population for iatrogenic anemia due to frequent monitoring requirements and multiple interventions:

Monitoring Strategies: Implementing protocols that specify the minimum frequency and volume of blood draws can significantly reduce iatrogenic blood loss. Consider consolidating multiple tests into single draws and eliminating routine "standing orders."

Alternative Monitoring:Non-invasive monitoring technologies, including continuous pulse oximetry, transcutaneous carbon dioxide monitoring, and non-invasive hemoglobin measurement, can reduce the need for blood sampling.

Nutritional Support: Early initiation of enteral or parenteral nutrition helps support erythropoiesis and recovery from anemia.

 Elderly Patients

Older adults face unique challenges related to iatrogenic anemia:

Cognitive Assessment: Anemia can exacerbate cognitive impairment in elderly patients, making recognition and treatment particularly important.

Medication Review: Comprehensive medication reconciliation to identify potentially contributory medications, with consideration of deprescribing when appropriate.

Functional Assessment:Evaluating the impact of anemia on activities of daily living and implementing supportive interventions as needed.

 Future Directions and Research Opportunities

Emerging Technologies

Several technological advances hold promise for reducing iatrogenic anemia:

Microfluidic Devices: Lab-on-a-chip technologies can perform multiple tests using minimal blood volumes (microliters vs. milliliters).

Non-Invasive Monitoring: Advances in spectroscopy and other non-invasive techniques may eventually eliminate the need for blood sampling for many routine tests.

Artificial Intelligence:Machine learning algorithms can optimize laboratory testing by predicting which tests are likely to change management and eliminating unnecessary testing.

Conclusion

Iatrogenic anemia represents a significant, yet largely preventable, complication of modern medical care. The condition affects a substantial proportion of hospitalized patients and contributes to increased morbidity, mortality, and healthcare costs. The multifactorial nature of iatrogenic anemia requires comprehensive, systematic approaches to prevention and management.

Key strategies for reducing iatrogenic anemia include implementing blood conservation protocols, optimizing medication management, utilizing point-of-care testing, and adopting restrictive transfusion practices. Success requires multidisciplinary collaboration, provider education, and system-level quality improvement initiatives.

Healthcare institutions should prioritize the development of blood management programs that integrate evidence-based practices with innovative technologies. Regular monitoring and feedback mechanisms are essential to ensure sustained improvement in patient outcomes.

As medical care becomes increasingly complex, vigilance regarding iatrogenic complications becomes more important. By recognizing iatrogenic anemia as a quality indicator and implementing comprehensive prevention strategies, healthcare providers can significantly improve patient outcomes while reducing healthcare costs.

The future of iatrogenic anemia prevention lies in the integration of advanced technologies, personalized medicine approaches, and continued refinement of clinical practices based on emerging evidence. Continued research and innovation in this field will further enhance our ability to provide safe, effective medical care while minimizing unintended consequences.

References

1. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288(12):1499-1507.

2. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States. Crit Care Med. 2004;32(1):39-52.

3. Thavendiranathan P, Bagai A, Ebidia A, Detsky AS, Choudhry NK. Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. J Gen Intern Med. 2005;20(6):520-524.

4. Salisbury AC, Reid KJ, Alexander KP, et al. Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. Arch Intern Med. 2011;171(18):1646-1653.

5. Chant C, Wilson G, Friedrich JO. Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study. Crit Care. 2006;10(5):R140.

6. Koch CG, Li L, Sun Z, et al. Hospital-acquired anemia: prevalence, outcomes, and healthcare implications. J Hosp Med. 2013;8(9):506-512.

7. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340(6):409-417.

8. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med. 2011;365(26):2453-2462.

9. Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371(15):1381-1391.

10. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008;36(9):2667-2674.

11. Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med. 2009;37(12):3124-3157.

12. Murphy GJ, Pike K, Rogers CA, et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015;372(11):997-1008.

13. Retter A, Wyncoll D, Pearse R, et al. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. Br J Haematol. 2013;160(4):445-464.

14. Barr PJ, Brady SC, Hughes CM, McElnay JC. A review of the literature on the prevalence and outcomes of hospital-acquired anemia. J Blood Med. 2013;4:143-148.

15. Zimmerman JL, Dellinger RP, Strauss RG, et al. Multicenter cohort study of red blood cell use in intensive care units. Crit Care Med. 2010;38(12):2316-2323.

16. Whitehead NS, Williams LO, Meleth S, et al. The effect of laboratory testing on emergency department length of stay: a multivariable regression analysis. Acad Emerg Med. 2013;20(3):202-215.

17. Sanchez-Giron F, Alvarez-Mora F. Reduction of blood loss from laboratory testing in hospitalized adult patients using small-volume tubes. Arch Pathol Lab Med. 2008;132(12):1916-1919.

18. Patel N, Minhas N, Lehmann LE, et al. Blood sampling frequencies and volumes in critically ill patients: a descriptive cohort study. Crit Care. 2008;12(4):R102.

19. Perkins LE, Slaughter RE, Price EA, et al. Reducing blood loss and the need for transfusions in critically ill patients. Crit Care Med. 2005;33(11):2637-2642.

20. Shaffer C, Gunderson CG. Reducing blood culture contamination in the emergency department: it takes a team. J Emerg Nurs. 2017;43(4):306-311.

21. Fowler RA, Berenson M. Blood conservation in the intensive care unit. Crit Care Med. 2003;31(12 Suppl):S715-720.

22. Low LL, Liu N, Wang S, et al. Diagnostic blood losses and blood transfusion requirements in patients with acute myocardial infarction. Heart. 2003;89(6):651-656.

23. Mukhopadhyay A, Yip HS, Prabhuswamy D, et al. The use of a blood conservation device to reduce red blood cell transfusion requirements: a before and after study. Crit Care. 2010;14(1):R7.

24. MacIsaac CM, Presneill JJ, Boyce CA, et al. The influence of a blood conserving device on anaemia in intensive care patients. Anaesth Intensive Care. 2003;31(6):653-657.

25. Riessen R, Behmenburg M, Blumenstock G, et al. A simple "blood-saving bundle" reduces diagnostic blood loss and the transfusion rate in mechanically ventilated patients. PLoS One. 2015;10(9):e0138879.

26. Dolman HS, Evans K, Zimmerman LH, et al. Impact of minimizing diagnostic blood loss in the critically ill. Surgery. 2015;158(4):1083-1087.

27. Lyon AW, Chin AC, Slotsve GA, et al. Simulation of repetitive diagnostic blood loss and onset of iatrogenic anemia in critical care patients with a mathematical model. Comput Biol Med. 2013;43(2):84-90.

28. Smoller BR, Kruskall MS, Horowitz GL. Reducing adult phlebotomy blood loss with the use of pediatric-sized blood collection tubes. Am J Clin Pathol. 1989;91(6):701-703.

29. Foulke GE, Harlow DJ. Effective measures for reducing blood loss from diagnostic laboratory tests in intensive care unit patients. Crit Care Med. 1989;17(11):1143-1145.

30. Wisser D, Knecht A. Effect of blood sampling tubes on blood test results. Clin Lab. 2004;50(7-8):457-462.

31. Mukhopadhyay A, Yip HS, Prabhuswamy D, et al. The association of red blood cell transfusion and in-hospital mortality in patients admitted to the intensive care unit. Crit Care Med. 2006;34(9):2349-2354.

32. Vincent JL, Jaschinski U, Wittebole X, et al. Worldwide audit of blood transfusion practice in critically ill patients. Crit Care. 2018;22(1):102.

33. Karam O, Lacroix J, Robitaille N, et al. Association between length of storage of red blood cell units and outcome of critically ill children: a prospective observational study. Crit Care. 2010;14(2):R57.

34. Goel R, Patel EU, Cushing MM, et al. Association of perioperative red blood cell transfusions with venous thromboembolism in a North American registry. JAMA Surg. 2018;153(9):826-833.

35. Rohde JM, Dimcheff DE, Blumberg N, et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA. 2014;311(13):1317-1326.

36. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010;50(4):753-765.

37. Abraham I, Sun D. The cost of blood transfusion in Western Europe as estimated from six studies. Transfusion. 2012;52(9):1983-1988.

38. Ferraris VA, Davenport DL, Saha SP, et al. Surgical outcomes and transfusion of minimal amounts of blood in the operating room. Arch Surg. 2012;147(1):49-55.

39. Frank SM, Savage WJ, Rothschild JA, et al. Variability in blood and blood component utilization as assessed by an anesthesia information management system. Anesthesiology. 2012;117(1):99-106.

40. Goodnough LT, Shieh L, Hadhazy E, et al. Improved blood utilization using real-time consultation for appropriate transfusion. Transfusion. 2014;54(9):2358-2364.

41. García-Erce JA, Muñoz M, Bisbe E, et al. Predeposit autologous donation in spinal surgery: a multicentre study. Eur Spine J. 2004;13 Suppl 1:S34-39.

42. Goodnough LT, Maniatis A, Earnshaw P, et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth. 2011;106(1):13-22.

43. Munoz M, Gomez-Ramirez S, Kozek-Langeneker S, et al. 'Fit to fly': overcoming barriers to preoperative haemoglobin optimization in surgical patients. Br J Anaesth. 2015;115(1):15-24.

44. Spahn DR, Moch H, Hofmann A, Isbister JP. Patient blood management: the pragmatic solution for the problems with blood transfusions. Anesthesiology. 2008;109(6):951-953.

45. Ranucci M, Baryshnikova E, Castelvecchio S, Pelissero G. Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. Ann Thorac Surg. 2013;96(2):478-485.

46. Kulier A, Levin J, Moser R, et al. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation. 2007;116(5):471-479.

47. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011;378(9800):1396-1407.

48. Baron DM, Hochrieser H, Posch M, et al. Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients. Br J Anaesth. 2014;113(3):416-423.

49. Klein AA, Collier TJ, Brar MS, et al. The incidence and importance of anaemia in patients undergoing cardiac surgery in the UK - the first Association of Cardiothoracic Anaesthetists national audit. Anaesthesia. 2016;71(6):627-635.

50. Rössler J, Schoenrath F, Seifert B, et al. Iron deficiency is associated with higher mortality in patients undergoing cardiac surgery: a prospective study. Br J Anaesth. 2020;124(1):25-34.